COVID-19 Ushers In Surge of Global Pharma-Bio Capital Construction Investment Topping $14 Billion
Attachment: Map
SUGAR LAND--December 16, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--As demand soared across the world for products to prevent, cure or treat COVID-19, life science companies rushed to fill the need. The roster goes far beyond the big-name companies like Pfizer Incorporated (NYSE:PFE) (New York, New York) or Moderna Incorporated (NASDAQ:MRNA) (Cambridge, Massachusetts). Catalent Incorporated (NYSE:CTLT) (Somerset, Franklin Township, New Jersey), already a strong contract manufacturing organization (CMO) prior to the pandemic, gained major prominence as it invested millions to beef up capacity for everything from bulk biologicals (drug substance manufacturing) to fill-and-finish services. Some seemingly appeared overnight, such as Phlow Corporation (Richmond, Virginia) and ApiJect Systems Corporation (Stamford, Connecticut), as the clamor for a cure and the subsequent federal funding came into being.
Companies featured: Pfizer Incorporated (NYSE:PFE), Moderna Incorporated (NASDAQ:MRNA), Catalent Incorporated (NYSE:CTLT)
